WeVote

Bill

Bill

HR 7902

Safeguarding Women from Chemical Abortion Act

119th Congress Introduced by Mark Alford and 6 co-sponsors

Bill withdraws FDA approval for mifepristone and creates federal tort liability for providers, effectively banning medication abortion nationwide and allowing civil lawsuits for alleged drug-related harm.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 7902

Legislative bill overview

HR 7902 seeks to withdraw FDA approval for mifepristone (a medication used in chemical abortions) and establish a federal tort allowing women to sue for damages they claim resulted from use of the drug. The bill creates new federal legal liability for entities involved in dispensing or administering mifepristone for pregnancy termination.

Why is this important

This legislation would effectively prohibit access to medication abortion nationwide by invalidating existing FDA approval, overriding the agency's scientific determinations made through formal regulatory processes. It would create an entirely new category of federal tort law allowing civil litigation, potentially affecting doctors, pharmacies, and abortion providers while significantly impacting reproductive healthcare access for millions of Americans.

Potential points of contention

  • FDA authority and reversal of precedent: The bill overrides the FDA's 2023 decision to expand mifepristone access, raising questions about Congressional power to override independent agency determinations and scientific findings
  • Definition and causation of "harm": The bill establishes a tort without clearly defining what constitutes compensable harm or how causation would be established in litigation, potentially creating liability for unpredictable medical outcomes
  • Conflict with existing law: This conflicts with state laws that protect or permit medication abortion, creating enforcement and jurisdictional complications across different legal regimes

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.